Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ CTNM
$11.50 0.51 4.64%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 25 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
180.57M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
159.55M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
25.87M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-21.50 %

Upcoming events Contineum Therapeutics, Inc. Class A Common Stock

All events
No upcoming events scheduled

Stock chart Contineum Therapeutics, Inc. Class A Common Stock

Stock analysis Contineum Therapeutics, Inc. Class A Common Stock

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-3.62 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
1.43 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-3.99 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.52 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-26.97 -50.00

Price change Contineum Therapeutics, Inc. Class A Common Stock per year

3.51$ 20.08$
Min Max

Summary analysis Contineum Therapeutics, Inc. Class A Common Stock

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Contineum Therapeutics, Inc. Class A Common Stock

Revenue and net income Contineum Therapeutics, Inc. Class A Common Stock

All parameters

About company Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Address:
3565 General Atomics Court, San Diego, CA, United States, 92121
Company name: Contineum Therapeutics, Inc. Class A Common Stock
Issuer ticker: CTNM
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2024-04-05
Sector: Healthcare
Industry: Biotechnology
Site: https://www.contineum-tx.com